To sign up for our newsletter or print publications, please enter your contact information below.
In patients with renal-cell carcinoma who require co-administration of everolimus with strong CYP3A4 inducers, the everolimus dose may be increased in 5-mg increments, from 10 mg to 20 mg daily, without monitoring of serum trough levels. This recommendation, however, is based on predictive models and not on clinical data.2,3
This single-institution study led by Caroline Townley, PharmD, compares the use of the Onpro device and the manual injection of pegfilgrastim and discusses the potential implications of the findings.
